Bayer to support WHO and Stop Tuberculosis Partnership in fighting tuberculosis
- Details
- Category: Bayer
Bayer HealthCare has agreed to support the World Health Organization (WHO) and the Stop TB Partnership in the fight against multidrug-resistant tuberculosis (MDR-TB) by making 620,000 tablets of the antibiotic moxifloxacin available to WHO.
Merck and Serum Institute Announce Collaboration
- Details
- Category: Merck
Merck (NYSE: MRK), known outside the United States and Canada as MSD, and Serum Institute of India Limited, an Indian company, announced an agreement to work together to develop and commercialize a pneumococcal conjugate vaccine (PCV) for use in the emerging and developing world countries.
Results of ROCKET AF Study of Bayer’s Xarelto® (Rivaroxaban)
- Details
- Category: Bayer
Data published in the New England Journal of Medicine demonstrate that Bayer's once-daily, oral, direct Factor Xa inhibitor rivaroxaban (Xarelto®) successfully met the primary efficacy outcome while maintaining comparable overall bleeding rates versus warfarin in the ROCKET AF study.
Lundbeck's first half report 2011
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) reports second quarter revenue of DKK 4,100 million growing 9% compared to the same period last year. In constant exchange rates revenue for the quarter increased 13%.
Lilly Announces Review of Data on Long-Term Raloxifene Treatment
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) announced that data on EVISTA® (raloxifene HCl tablets) therapy for more than three years was published online in Current Medical Research & Opinion. The review includes summaries of previously published information; new, previously unpublished observations; and new data on EVISTA use.
Many Americans May Have Low Vitamin D Levels
- Details
- Category: Abbott
Data presented at the American Association for Clinical Chemistry (AACC) meeting showed that many people have low vitamin D levels and that testing individuals at risk may be beneficial.
Roche's investigational treatment for asthma met its primary endpoint
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a phase II study of its investigational treatment lebrikizumab, a humanized monoclonal antibody designed to block interleukin-13 (IL-13) cytokine, met its primary endpoint.
More Pharma News ...
- Bristol-Myers Squibb Delivers Excellent Second Quarter
- NCCN Receives $2M Educational Grant from Pfizer
- Pfizer Reports Second-Quarter 2011 Results
- Sanofi's sales growth of 6.9% thanks to Genzyme acquisition
- Bayer continues positive momentum
- Amgen's Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
- AstraZeneca PLC Second quarter and half year results 2011